Magnetic Ventures
VC Fund
San Francisco, United States
Magnetic Ventures is a VC fund in San Francisco focused on Biotechnology and Health Care. Magnetic Ventures focuses on early stage investing at the intersection of life science and technology.
- Total investments:
- 22
- Last investment:
- Lead investor:
- 23%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Magnetic Ventures invests in
Stages Magnetic Ventures invests in
Countries Magnetic Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Umut Eser
|
|||
Investment Focus
Industry
- Biotechnology 10 (45%)
- Health Care 9 (41%)
- Medical 6 (27%)
- Life Science 4 (18%)
- Artificial Intelligence 4 (18%)
Stage
- Seed 7 (32%)
- Series A 6 (27%)
- Series B 5 (23%)
- Series C 2 (9%)
- Venture - Series Unknown 1 (5%)
Country
- United States 11 (50%)
- Germany 2 (9%)
- Canada 1 (5%)
- United Kingdom 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Christine Aylward
Founder & Managing Partner
|
Founder & Managing Partner | Total investments: 8 | Find email | |
|
Umut Eser
Venture Partner
|
Venture Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
SE3 Labs
|
SE3 Labs creates Spatial AI tools to improve real-time awareness in defense, construction, and smart systems. | $6.3M / Seed / Jun 26, 2026 | |
Proxima
|
Proxima Bio develops programmable medicines that modulate protein interactions to address disease processes. It focuses on creating proximity-modulating therapeutics that direct protein interactions for potential use in conditions such as autoimmune disorders and cancer, expanding the range of targets that traditional drugs cannot easily reach.Proxima Bio combines structural biology, data generation, and machine learning to identify actionable protein-protein interfaces and support the discovery of new therapeutic modalities. The company works with pharmaceutical partners to apply its platform in research collaborations and advance drug discovery pipelines. Proxima Bio’s platform integrates multiple technologies to support the design and discovery of novel proximity-based treatment approaches. | $86.3M / Seed / Jan 13, 2026 | |
Relation Therapeutics
|
Relation Therapeutics is a biotechnology company that focuses on humanizing drug discovery and development. It leverages human genetics and clinical omics data and utilizes patient-derived tissue samples with functional genomics interventional experiments to identify, validate, and prosecute therapeutic programs. | $26M / Venture - Series Unknown / Dec 09, 2025 | |
Weave
|
Weave provides an artificial intelligence collaboration platform for biomedicine. The company is headquartered in the United States. | $20M / Series A / Oct 16, 2025 | |
Terrain Bio
|
Terrain BioSciences is in the field of RNA-based therapeutics and vaccine development. Leveraging advanced AI and proprietary manufacturing platforms, Terrain BioSciences addresses the challenges of designing, selecting, manufacturing, and delivering optimal RNA sequences. Terrain BioSciences collaborates with over a dozen biotech firms to enhancethe expression, durability, and manufacturability of RNA sequences, significantly accelerating their path to clinical application. With a focus on personalized cancer vaccines and other RNA-based modalities, Terrain BioSciences is at the forefront of the next generation of programmable medicines. | $9M / Seed / Feb 12, 2025 | |
|
Weave
|
Weave provides an artificial intelligence collaboration platform for biomedicine. The company is headquartered in the United States. | $10M / Seed / May 30, 2024 | |
|
Relation Therapeutics
|
Relation Therapeutics is a biotechnology company that focuses on humanizing drug discovery and development. It leverages human genetics and clinical omics data and utilizes patient-derived tissue samples with functional genomics interventional experiments to identify, validate, and prosecute therapeutic programs. | $35M / Seed / Mar 14, 2024 | |
Paradigm
|
Paradigm is rebuilding the clinical research ecosystem by developing a platform that allows all patients equitable access to trials while improving trial efficiency and lowering barriers to participation for healthcare providers. | $203M / Series A / Jan 25, 2023 | |
Project Eaden
|
Project Eaden combines pioneering technology with an immense love for life and food. | $8.4M / Seed / Jun 30, 2022 | |
|
Relation Therapeutics
|
Relation Therapeutics is a biotechnology company that focuses on humanizing drug discovery and development. It leverages human genetics and clinical omics data and utilizes patient-derived tissue samples with functional genomics interventional experiments to identify, validate, and prosecute therapeutic programs. | $25M / Seed / Jun 09, 2022 | |
| See all 22 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Magnetic Ventures invest in?
Magnetic Ventures invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Series A stage. Most of the 22 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Magnetic Ventures?
Public channels for Magnetic Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Magnetic Ventures?
The team at Magnetic Ventures includes Christine Aylward (Founder & Managing Partner) and Umut Eser (Venture Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
